Rexahn Pharmaceuticals, a key player in development of innovative therapeutics for life-threatening and life-debilitating diseases, announced that it has received FDA approval to begin phase II trials for ArchexinÔ, its leading cancer compound, for the treatment of pancreatic cancer

More: continued here